FOXO Technologies Inc

FOXO Technologies Inc. pioneers epigenetic‑driven underwriting and engagement, serving insurers, researchers, and life‑science firms worldwide despite market volatility.

FOXO Technologies Inc.

FOXO Technologies Inc. uses epigenetic tech to transform insurance underwriting and consumer engagement, driving innovation despite volatile stock performance.

FOXO Technologies Inc. pioneers epigenetic software for insurers and researchers, offering global underwriting and consumer‑engagement solutions that redefine data‑driven healthcare insights.

FOXO Technologies Inc., a software company specializing in epigenetic technology, has seen its stock price decline significantly from a 52-week high of $25.8964 to $0.156 as of July 31, 2025, due to broader market challenges and shifting investor se…

FOXO Technologies Inc. has been delisted from the NYSE American and will now trade on the Over-the-Counter (OTC) market, effective August 13, 2025.

FOXO Technologies Inc. faces significant market challenges and financial struggles despite its innovative approach to integrating epigenetic technology with software solutions.

FOXO Technologies Inc. has completed a reverse stock split, aiming to adjust its stock price and attract a new investor base, following a year of significant stock price fluctuations.